Elekta AB ser. B shares moved lower in today’s session, declining 3.9% to trade at 49.6 SEK as investors digested the group’s Capital Markets Day (CMD) in Stockholm. The company’s CEO and CFO used the event to set out strategic priorities and mid-term financial targets intended to reassure the market after a difficult Q4 2025/26 reporting period.
At the CMD, management set a mid-term sales growth goal of mid-single digit compound annual growth in constant currency for the period from fiscal year 2025/26 through fiscal year 2028/29. The company also laid out an adjusted EBIT margin target of 14% to 16% for FY 2028/29, and a target for free cash flow before dividend of approximately 10% of sales in that same year.
These targets were presented against the backdrop of the company’s Q4 2025/26 results, released on May 28, which had previously triggered a sharp share reaction after the company reported weak order intake and missed sales estimates. The CMD had been framed as a chance for management to restore confidence with investors and analysts, but the guidance appears to have been insufficient to turn sentiment during the session.
Market participants brought a level of skepticism into the event. Notable sell-side positions include UBS, which maintains a "sell" rating on the stock and has pointed to a weakening outlook, while Morgan Stanley remains "underweight." Those analyst stances align with a broader increase in short interest in the shares in recent weeks.
On a relative basis, the stock is trading about 26% below its 52-week high of 66.7 SEK, underscoring the distance investors perceive between current performance and prior peaks. Intraday the shares reached a low of 49.54 SEK as selling persisted.
External market forces compounded company-specific concerns. The Swedish equity market has shown softness in recent sessions, and major U.S. indices were weaker today with the NASDAQ and the S&P 500 both trading lower. The medtech sector more broadly is entering the second half of 2026 with subdued expectations, which adds a layer of macroeconomic and sector-wide headwind to Elekta’s challenges.
Taken together, the combination of mid-term targets that some investors view as tepid or lacking credibility, ongoing analyst caution, rising short interest and a risk-off trading environment drove the stock lower during the session. Management highlighted strategic priorities that include strengthening presence in the U.S. and expanding in China, but the market reaction indicates doubts remain about the company’s near-term growth trajectory and the ability of the new leadership team to close the gap.
Summary
Elekta’s CMD produced mid-term goals for mid-single digit sales CAGR, an adjusted EBIT margin of 14% to 16% and roughly 10% free cash flow before dividend as a percentage of sales by FY 2028/29. In the context of recent weak quarterly results, analyst caution and a softer market backdrop, the stock fell to 49.6 SEK during the trading session.